Global Regenerative Medicine Market Report 2021-2027 - Regenerative Medicine Field Lags Behind Due to Segregated Focus
Dublin, Aug. 18, 2021 (GLOBE NEWSWIRE) -- The "Regenerative Medicine - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Global Regenerative Medicine Market to Reach $50.2 Billion by 2027
Amid the COVID-19 crisis, the global market for Regenerative Medicine estimated at US$12.2 Billion in the year 2020, is projected to reach a revised size of US$50.2 Billion by 2027, growing at a CAGR of 22.3% over the analysis period 2020-2027.
Cell Therapy, one of the segments analyzed in the report, is projected to record a 23.3% CAGR and reach US$25.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gene Therapy segment is readjusted to a revised 21.9% CAGR for the next 7-year period.
The U.S. Market is Estimated at $3.7 Billion, While China is Forecast to Grow at 21.8% CAGR
The Regenerative Medicine market in the U.S. is estimated at US$3.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$8.7 Billion by the year 2027 trailing a CAGR of 21.8% over the analysis period 2020 to 2027.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 20.1% and 18.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.6% CAGR.
Tissue Engineering Segment to Record 21.1% CAGR
In the global Tissue Engineering segment, USA, Canada, Japan, China and Europe will drive the 21% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.7 Billion in the year 2020 will reach a projected size of US$6.3 Billion by the close of the analysis period.
China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5.9 Billion by the year 2027.
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Regenerative Medicine: A Preface
Recent Market Activity
An Overview of Regenerative Medicine in Bone and Joint Applications
Current and Future Analysis
Developed Markets Dominate, Developing to Drive Growth
Regenerative Medicine - Past, Present & Future
Another Revolution in the Making?
Conventional Chemical Medicine Vs Regenerative Medicine
Regenerative Medicine - Bypassing the Ethical Concerns
Regenerative Medicine Throws Up Several New Therapies
Current Global Market for Regenerative Medicine
Market Potential
Therapeutic Companies and Products in Regenerative Medicine - Current Status
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
AlloSource (US)
Anika Therapeutics, Inc. (US)
Bioventus LLC (US)
DePuy Synthes Companies (US)
DePuy Synthes Spine, Inc. (US)
Exactech, Inc. (US)
Integra LifeSciences Holdings Corp. (US)
LifeNet Health, Inc. (US)
Medtronic, plc (Ireland)
NovaBone Products LLC (US)
NuVasive, Inc. (US)
Orthofix International N.V. (Netherlands)
Osiris Therapeutics, Inc. (US)
Smith & Nephew plc (UK)
Stryker Corporation (US)
Wright Medical Technology, Inc. (US)
Zimmer Biomet Holdings, Inc. (US)
3. MARKET TRENDS & DRIVERS
A Combination of Factors to Drive Regenerative Medicine Market
Burgeoning Global Population Offers Significant Growth Opportunities
Aging Global Population: Need for New Effective Treatments
Increasing Healthcare Spending in Emerging Markets: Opportunities in Store
Government Support and Increased Private Sector Participation
Investment and Funding Landscape
Major M&A Activity and Strategic Alliances in Regenerative Medicine: 2011-2016
Recent Advancements in the Science of Regenerative Medicine
Advanced Ceramics Gaining Preeminence in Regenerative Medicine Field
3D Organ & Tissue Printing: Still in Early Stages
Nanotechnology in Regenerative Medicine
Issues to be Sorted Out
Need for New Scientific and Technological Standards
Standardized Guidelines
Clinical Translation - Collaboration of Multidisciplinary Skills is Essential
The Question of Apt Business Models - The Service and Product Approach
Autologous or Service Approach Preferred by European Firms
Allogenic or Product Approach - Slow to Develop
Regenerative Medicine Requires Improved Biomaterials
Investors Wary of Funding Regenerative Medicine
Regenerative Medicine Field Lags Behind Due to Segregated Focus
Challenges Encountered by Regenerative Medicine
Scientific and Technological Challenges
Barriers in Sharing Intellectual Property Rights
Viable Manufacturing Technologies and Skilled Personnel Crucial
Strict Regulations Push up Operational Costs
Challenges Facing Autologous Cell Therapies
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
United States
Canada
Japan
China
Europe
France
Germany
Italy
United Kingdom
Spain
Russia
Rest Of Europe
Asia-Pacific
Australia
India
South Korea
Rest Of Asia-Pacific
Latin America
Argentina
Brazil
Mexico
Rest Of Latin America
Middle East
Iran
Israel
Saudi Arabia
United Arab Emirates
Rest Of Middle East
Africa
IV. COMPETITION
Total Companies Profiled: 52
For more information about this report visit https://www.researchandmarkets.com/r/qbjqv0
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900